% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Selt:130542,
      author       = {F. Selt$^*$ and A. Deiß$^*$ and A. Korshunov$^*$ and D.
                      Capper$^*$ and H. Witt$^*$ and C. M. van Tilburg$^*$ and D.
                      Jones$^*$ and R. Witt$^*$ and F. Sahm$^*$ and D. Reuss$^*$
                      and C. Kölsche$^*$ and J. Ecker$^*$ and I. Oehme$^*$ and T.
                      Hielscher$^*$ and A. von Deimling$^*$ and A. E. Kulozik and
                      S. Pfister$^*$ and O. Witt$^*$ and T. Milde$^*$},
      title        = {{P}ediatric {T}argeted {T}herapy: {C}linical {F}easibility
                      of {P}ersonalized {D}iagnostics in {C}hildren with
                      {R}elapsed and {P}rogressive {T}umors.},
      journal      = {Brain pathology},
      volume       = {26},
      number       = {4},
      issn         = {1015-6305},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-05621},
      pages        = {506 - 516},
      year         = {2016},
      abstract     = {The 'pediatric targeted therapy' (PTT) program aims to
                      identify the presence and activity of druggable targets and
                      evaluate the clinical benefit of a personalized treatment
                      approach in relapsed or progressive tumors on an individual
                      basis. 10 markers (HDAC2, HR23B, p-AKT, p-ERK, p-S6, p-EGFR,
                      PDGFR-alpha/beta, p53 and BRAFV600E) were analyzed by
                      immunohistochemistry. Pediatric patients with tumors
                      independent of the histological diagnosis, with relapse or
                      progression after treatment according to standard protocols
                      were included. N = 61/145 $(42\%)$ cases were eligible
                      for analysis between 2009 and 2013, the most common entities
                      being brain tumors. Immunohistochemical stainings were
                      evaluated by the H-Score (0-300). In $93\%$ of the cases
                      potentially actionable targets were identified. The
                      expressed or activated pathways were histone deacetylase
                      (HDACs; $83.0\%$ of cases positive), EGFR $(87.2\%),$ PDGFR
                      $(75.9\%),$ p53 $(50.0\%),$ MAPK/ERK $(43.3\%)$ and
                      PI3K/mTOR $(36.1\%).$ Follow-up revealed partial or full
                      implementation of PTT results in treatment decision-making
                      in $41\%$ of the cases. Prolonged disease stabilization
                      responses in single cases were noticed, however, response
                      rates did not differ from cases treated with other
                      modalities. Further studies evaluating the feasibility and
                      clinical benefit of personalized diagnostic approaches using
                      paraffin material are warranted.},
      cin          = {G340 / G380 / B062 / C060 / G040 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)G340-20160331 / I:(DE-He78)G380-20160331 /
                      I:(DE-He78)B062-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G040-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26445087},
      doi          = {10.1111/bpa.12326},
      url          = {https://inrepo02.dkfz.de/record/130542},
}